证券代码：301009 证券简称：可靠股份 公告编号：2026-003 杭州可靠护理用品股份有限公司 一、董事会会议召开情况 杭州可靠护理用品股份有限公司（以下简称"公司"）第五届董事会第十五 次（临时）会议于 2026 年 1 月 23 日在杭州市余杭区向往街 1118 号英国中心 T6-28 层公司会议室以现场结合网络会议方式召开，会议通知已于 2026 年 1 月 19 日以 电话及电子邮件等方式送达全体董事。本次会议应出席董事 7 人，实际出席董事 7 人（其中董事鲍佳女士、独立董事寿泓先生、独立董事肖炜麟先生以网络会议 方式审议表决，独立董事景乃权先生授权委托独立董事寿泓先生代为出席并行使 表决权），会议由董事长金利伟先生主持，公司部分高级管理人员列席。会议召 开符合有关法律、法规、规章和《公司章程》的规定。 二、董事会会议审议情况 1、审议通过《关于选举代表公司执行公司事务的董事的议案》 经与会董事审议，根据相关监管要求及公司经营发展需要，依据《中华人民 共和国公司法》《上市公司章程指引》和《公司章程》的有关规定，同意选举董 事长金利伟先生为代表公司执行公司事务的董事，并担任公司法定代表人，任期 ...

Core Viewpoint - Bailitianheng is a comprehensive enterprise focusing on cutting-edge global biomedicine, particularly in the field of tumor macromolecule therapy, with a strategic goal of becoming a multinational corporation (MNC) dedicated to addressing unmet clinical needs in cancer treatment [1] Group 1: Company Overview - Bailitianheng specializes in innovative research and development, global clinical development, and large-scale production capabilities in the tumor macromolecule therapy sector [1] - The company aims to build a full industry chain covering research, clinical trials, production, and commercialization, aspiring to become a leading multinational pharmaceutical enterprise in cancer treatment [1] Group 2: Clinical Needs and Innovations - Nasopharyngeal carcinoma is a highly prevalent malignant tumor in China, with limited treatment options for late-stage patients, highlighting a significant clinical need for new therapeutic mechanisms [1] - In addition to nasopharyngeal carcinoma, China has the highest incidence and mortality rates for esophageal cancer globally, with a pressing demand for effective second-line treatment options [1] Group 3: Product Development - Bailitianheng has developed iza-bren, a first-in-class EGFR×HER3 dual-target ADC drug, which is currently the only dual-target ADC in Phase III clinical trials [2] - Iza-bren utilizes a dual-target design to precisely deliver cytotoxic payloads to tumor cells while minimizing damage to normal cells, enhancing efficacy and reducing adverse reactions [2] Group 4: Clinical Trial Results - The Phase III study BL-B01D1-303 for recurrent or metastatic nasopharyngeal carcinoma patients showed a 54.6% objective response rate (ORR), significantly higher than the 27.0% for standard chemotherapy, and a median progression-free survival (mPFS) of 8.38 months compared to 4.34 months for chemotherapy [3] - The study results have been recognized internationally, with findings selected for presentation at the 2025 ESMO conference and published in The Lancet [3] Group 5: Regulatory Progress - Iza-bren has been included in the priority review list by the CDE and has received acceptance for its new drug application for nasopharyngeal carcinoma by the NMPA [3] - The Phase III study BL-B01D1-305 for esophageal squamous cell carcinoma achieved positive results for both progression-free survival (PFS) and overall survival (OS), marking a significant milestone for ADC drugs in this field [4] Group 6: Industry Impact - Iza-bren represents a successful example of clinical translation for dual-target ADC technology, showcasing Bailitianheng's research capabilities in tumor macromolecule therapy [4] - The successful commercialization of iza-bren is expected to reshape treatment paradigms for late-stage nasopharyngeal carcinoma and esophageal squamous cell carcinoma, providing new hope for patients who have failed previous treatments [4][5] Group 7: Future Outlook - With the commercialization of iza-bren and the advancement of more innovative pipelines, the company aims to lead the development of innovative cancer therapies and contribute to the global narrative of China's biopharmaceutical industry [5]

Market Overview - The personal care products sector increased by 0.76% on January 21, with Yanjiang Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Stock Performance - Yanjiang Co., Ltd. (300658) closed at 20.90, up 7.73% with a trading volume of 595,600 shares and a transaction value of 1.202 billion yuan [1] - Beijia Clean (603059) closed at 38.66, up 6.27% with a trading volume of 51,500 shares and a transaction value of 195 million yuan [1] - Jeya Co., Ltd. (301108) closed at 37.08, up 2.01% with a trading volume of 20,700 shares and a transaction value of 75.4978 million yuan [1] - Baiya Co., Ltd. (003006) closed at 22.96, up 2.00% with a trading volume of 133,100 shares and a transaction value of 302 million yuan [1] - Reliable Co., Ltd. (301009) closed at 13.57, up 0.89% with a trading volume of 35,200 shares and a transaction value of 47.5696 million yuan [1] Capital Flow - The personal care products sector experienced a net outflow of 15.344 million yuan from institutional investors, while retail investors saw a net outflow of 22.6944 million yuan [2] - However, speculative funds recorded a net inflow of 38.0385 million yuan [2] Detailed Capital Flow Analysis - Baiya Co., Ltd. (003006) had a net inflow of 55.3986 million yuan from institutional investors, while retail investors had a net outflow of 45.3097 million yuan [3] - Beijia Clean (603059) saw a net inflow of 9.3501 million yuan from institutional investors and a net outflow of 2.32565 million yuan from retail investors [3] - Jeya Co., Ltd. (301108) experienced a net outflow of 6.1734 million yuan from institutional investors, while retail investors had a net inflow of 7.5396 million yuan [3]

Group 1 - The core point of the article indicates that Reliable Co., Ltd. (stock code: 301009) reported a slight decrease in the total number of shareholders, from 17,604 as of September 30, 2025, to 16,620 as of December 31, 2025 [1]

Core Viewpoint - The company has received formal acceptance for the New Drug Application (NDA) of its self-developed, globally innovative EGFR×HER3 dual antibody ADC, which is the only one to enter Phase III clinical trials [1] Group 1 - The drug, named iza-bren, has achieved dual primary endpoints of progression-free survival and overall survival in a Phase III clinical trial for esophageal squamous cell carcinoma, as determined by an independent data monitoring committee during a pre-set interim analysis [1] - The NDA acceptance is based on the interim analysis results from the Phase III clinical trial [1] - Iza-bren has been included in the priority review list by the Center for Drug Evaluation (CDE) for the treatment of recurrent or metastatic esophageal squamous cell carcinoma [1]

Core Insights - The National Medical Products Administration (NMPA) has accepted a new drug application for the first-in-class dual antibody ADC drug, iza-bren, developed by BaiLi Tianheng, aimed at treating recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after failure of PD-1/PD-L1 monoclonal antibody combined with platinum-based chemotherapy [1][2] - The application is based on positive results from a Phase III clinical trial, which met both primary endpoints of progression-free survival (PFS) and overall survival (OS) in a pre-specified interim analysis [1] - Esophageal cancer has a significant global burden, with approximately 510,000 new cases and 445,000 deaths annually, and China accounts for about 224,000 new cases, representing 43.8% of the global total [1] Group 1 - Iza-bren has shown anti-tumor activity, safety, and efficacy in a Phase Ib clinical study published in the journal Nature Medicine [2] - Currently, over 40 clinical studies are ongoing for iza-bren in China and the U.S., including 10 registration Phase III studies in China and 3 global pivotal registration studies [2] - Seven indications for iza-bren have been included in the breakthrough therapy designation list by the CDE, and one indication has been designated as breakthrough therapy by the FDA [2] Group 2 - There are currently only 10 new biological drugs approved for esophageal cancer treatment globally, with no ADCs approved yet [3] - If approved, BL-B01D1 will become the first ADC drug for the treatment of esophageal cancer worldwide [3]

Group 1 - The personal care products sector increased by 1.77% on January 20, with Yanjiang Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] - Key stocks in the personal care sector showed varied performance, with Yanjiang Co., Ltd. closing at 19.40, up 9.11%, and Ziya Co., Ltd. at 22.51, up 4.16% [1] Group 2 - The personal care products sector experienced a net outflow of 47.99 million yuan from institutional investors, while retail investors saw a net inflow of 9.42 million yuan [2] - The trading volume for Yanjiang Co., Ltd. was 638,400 shares, with a total transaction value of 1.257 billion yuan [1] - The stock performance of major companies included a 2.51% increase for Beijia Co. and a 2.25% increase for Dengkang Oral Care [1][2] Group 3 - The net inflow from retail investors for the stock of Yiyi Co. was 400.92 million yuan, while the net outflow from institutional investors was 595.82 million yuan for Kela Co. [3] - The net inflow for Ziya Co. was 299.34 million yuan from retail investors, while it faced a net outflow of 1,407.33 million yuan from institutional investors [3] - The overall market sentiment showed mixed results, with some stocks like Yiyi Co. and Beijia Co. attracting retail interest despite institutional outflows [3]

Core Viewpoint - The personal care products sector experienced a 1.96% increase on January 19, with Yanjiang Co., Ltd. leading the gains, while the Shanghai Composite Index rose by 0.29% and the Shenzhen Component Index increased by 0.09% [1] Group 1: Market Performance - The closing price of Yanjiang Co., Ltd. was 17.78, reflecting a significant increase of 19.97% with a trading volume of 767,100 shares and a transaction value of 1.28 billion yuan [1] - Baiya Co., Ltd. closed at 21.61, up by 4.60%, with a trading volume of 130,400 shares and a transaction value of 283 million yuan [1] - Reliable Co., Ltd. saw a closing price of 13.46, increasing by 2.12% with a trading volume of 32,300 shares [1] Group 2: Fund Flow Analysis - The personal care products sector had a net outflow of 50.30 million yuan from institutional investors, while retail investors saw a net inflow of 17.49 million yuan [2] - The main funds showed a net inflow of 7.99 million yuan into Stable Medical, while the retail funds had a net outflow of 16.41 million yuan [3] - In contrast, Jingya Co., Ltd. experienced a net outflow of 3.24 million yuan from main funds, but retail funds showed a net inflow of 5.23 million yuan [3]

证券日报网讯 1月16日，可靠股份发布公告称，公司2026年第一次临时股东大会审议通过《关于修订及 相关议事规则的议案》。 （文章来源：证券日报） ...

证券代码：301009 证券简称：可靠股份 公告编号：2026-002 杭州可靠护理用品股份有限公司 任绍楠先生符合《公司法》《公司章程》规定的有关职工代表董事任职的资格 和条件。此次选举产生职工代表董事后，公司第五届董事会构成人数不变，董事人 数符合相关法律法规和规范性文件的规定，董事会中兼任公司高级管理人员以及由 职工代表担任的董事人数未超过公司董事总数的二分之一，符合相关法律法规的要 求。 关于非独立董事调整暨选举职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 杭州可靠护理用品股份有限公司（以下简称"公司"）于 2025 年 12 月 31 日 召开了第五届董事会第十四次（临时）会议，并于 2026 年 1 月 16 日召开了 2026 年第一次临时股东大会，审议通过了《关于修订<公司章程>及相关议事规则的议案》。 根据修订后的《公司章程》规定，在维持现状"董事会由七名董事组成"的情况下， 公司设 1 名职工代表董事。 一、非独立董事调整情况 公司董事会于今日收到公司第五届董事会非独立董事程岩传先生递交的书面 辞职报告。因公司治理结构 ...